FR3000896B1 - Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil - Google Patents
Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeilInfo
- Publication number
- FR3000896B1 FR3000896B1 FR1350308A FR1350308A FR3000896B1 FR 3000896 B1 FR3000896 B1 FR 3000896B1 FR 1350308 A FR1350308 A FR 1350308A FR 1350308 A FR1350308 A FR 1350308A FR 3000896 B1 FR3000896 B1 FR 3000896B1
- Authority
- FR
- France
- Prior art keywords
- sleep
- administration
- treatment
- active ingredient
- galenic form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1350308A FR3000896B1 (fr) | 2013-01-14 | 2013-01-14 | Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil |
JP2015552133A JP2016504405A (ja) | 2013-01-14 | 2014-01-14 | ガレヌス製剤の有効成分の投与剤形 |
BR112015016869A BR112015016869A2 (pt) | 2013-01-14 | 2014-01-14 | forma de dosagem para a administração de um princípio ativo para indução acelerada do sono e/ou para o tratamento de distúrbios do sono e/ou para tratar um distúrbio do sistema nervoso central |
CA2897685A CA2897685A1 (fr) | 2013-01-14 | 2014-01-14 | Forme galenique pour l'administration d'un principe actif |
US14/759,822 US20150352038A1 (en) | 2013-01-14 | 2014-01-14 | A dosage form for administering an active principle for accelerated sleep induction and/or for treating sleep disorders and/or for treating a central nervous system disorder |
CN201480011684.3A CN105025880A (zh) | 2013-01-14 | 2014-01-14 | 用于施用活性成分的盖仑氏形式 |
EP14703148.8A EP2943182A1 (fr) | 2013-01-14 | 2014-01-14 | Forme galenique pour l'administration d'un principe actif |
PCT/FR2014/050070 WO2014108657A1 (fr) | 2013-01-14 | 2014-01-14 | Forme galenique pour l'administration d'un principe actif |
RU2015134148A RU2015134148A (ru) | 2013-01-14 | 2014-01-14 | Галеновая форма для введения активного действующего вещества |
MX2015009027A MX2015009027A (es) | 2013-01-14 | 2014-01-14 | Forma galenica para la administracion de un principio activo. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1350308A FR3000896B1 (fr) | 2013-01-14 | 2013-01-14 | Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil |
Publications (2)
Publication Number | Publication Date |
---|---|
FR3000896A1 FR3000896A1 (fr) | 2014-07-18 |
FR3000896B1 true FR3000896B1 (fr) | 2016-08-26 |
Family
ID=48170667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1350308A Expired - Fee Related FR3000896B1 (fr) | 2013-01-14 | 2013-01-14 | Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil |
Country Status (10)
Country | Link |
---|---|
US (1) | US20150352038A1 (fr) |
EP (1) | EP2943182A1 (fr) |
JP (1) | JP2016504405A (fr) |
CN (1) | CN105025880A (fr) |
BR (1) | BR112015016869A2 (fr) |
CA (1) | CA2897685A1 (fr) |
FR (1) | FR3000896B1 (fr) |
MX (1) | MX2015009027A (fr) |
RU (1) | RU2015134148A (fr) |
WO (1) | WO2014108657A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3031668A1 (fr) | 2015-01-20 | 2016-07-22 | Philippe Perovitch | Dispositif d'administration d'un principe actif par voie per-muqueuse buccale. |
EP3337480A4 (fr) * | 2015-08-17 | 2019-05-08 | Aequus Pharmaceuticals Inc. | Administration transdermique de succinate de doxylamine et de chlorhydrate de piridoxine |
RU2620855C1 (ru) * | 2016-02-18 | 2017-05-30 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция для профилактики и лечения нарушений сна |
FR3053244A1 (fr) | 2016-07-01 | 2018-01-05 | Philippe Perovitch | Dispositif d'administration d'au moins un principe actif par voie per-muqueuse buccale. |
CN110996938A (zh) * | 2017-07-13 | 2020-04-10 | 美治医药科技有限公司 | 雷美替胺的药物组合物及其使用方法 |
WO2021258326A1 (fr) * | 2020-06-24 | 2021-12-30 | 中国人民解放军军事科学院军事医学研究院 | Application de nanocristaux de midazolam dans la préparation d'un médicament destiné à améliorer la perméabilité de la barrière hémato-encéphalique |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0518468T3 (da) | 1991-05-09 | 2000-01-31 | Neurim Pharma 1991 | Melatoninholdige sammensætninger |
FR2754454B1 (fr) | 1996-10-10 | 1998-11-27 | Oreal | Utilisation d'au moins un glycol comme agent de solubilisation de la melatonine dans l'eau et compositions obtenues |
US20050163719A1 (en) | 1997-10-01 | 2005-07-28 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing diazepam |
US7632517B2 (en) | 1997-10-01 | 2009-12-15 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
IL130171A (en) | 1999-05-27 | 2004-06-01 | Neurim Pharma 1991 | Melatonin for use in preventing and treating tardive dyskinesia, pharmaceutical preparations containing it and its use in the manufacture of medicines |
EP1715853A4 (fr) * | 2004-02-17 | 2012-07-18 | Transcept Pharmaceuticals Inc | Compositions permettant d'administrer des agents hypnotiques dans la muqueuse orale et methodes d'utilisation |
EP2767163A1 (fr) * | 2005-02-17 | 2014-08-20 | Abbott Laboratories | Administration par voie transmuqueuse de compositions médicamenteuses pour le traitement et la prévention de troubles chez les animaux |
US20070225322A1 (en) * | 2005-05-25 | 2007-09-27 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the night insomnia |
ZA200710205B (en) * | 2005-05-25 | 2009-03-25 | Transcept Pharmaceuticals Inc | Solid compositions and methods for treating middle-of-the night insomnia |
FR2894475B1 (fr) * | 2005-12-14 | 2008-05-16 | Servier Lab | Composition pharmaceutique orodispersible pour administra- -tion oromucosale ou sublinguale d'agomelatine |
KR20070079792A (ko) | 2006-02-03 | 2007-08-08 | 삼성전자주식회사 | 디스크리트 타임 발진기를 이용한 모터 구동회로와 그 방법 |
ITRM20060108A1 (it) | 2006-03-03 | 2007-09-04 | Colella Gino | Composizioni a base di melatonina e sostanze immunostimolanti |
CA2649895C (fr) | 2006-04-19 | 2013-03-26 | Novadel Pharma Inc. | Formulations hydroalcooliques stables a pulveriser dans la cavite buccale et procedes associes |
FR2906140B1 (fr) * | 2006-09-22 | 2008-12-05 | Philippe Perovitch | Forme galenique pour l'administration par voie trans-muqueuse de principes actifs |
FR2910317B1 (fr) * | 2006-12-21 | 2009-02-13 | Philippe Perovitch | Forme galenique pour l'administration par voie transmuqueuse de paracetamol |
CA2678500A1 (fr) * | 2007-02-15 | 2008-08-21 | Derma-Young Ltd. | Compositions et methodes permettant d'ameliorer l'administration transmuqueuse |
JP2010526837A (ja) * | 2007-05-10 | 2010-08-05 | ノヴァデル ファーマ インコーポレイテッド | 抗不眠症組成物および方法 |
FR2918874B1 (fr) | 2007-07-20 | 2009-10-09 | Philippe Perovitch | Dispositif de conditionnement et d'administration sub-linguale de principes actifs |
EP2182902B1 (fr) * | 2007-08-07 | 2015-01-07 | Acelrx Pharmaceuticals, Inc. | Compositions comprenant du sufentanil and de la triazolame pour leur utilisation dans la sédation et l'analgésie procédurales utilisant les formes posologiques transmucosales orales |
FR2926721B1 (fr) * | 2008-01-30 | 2011-07-22 | Philippe Perovitch | Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans |
FR2930140B1 (fr) | 2008-04-17 | 2011-04-22 | Philippe Perovitch | Dispositif pour la conservation, la preparation extemporanee et l'administration d'un faible dosage de principe actif |
FR2939321B1 (fr) | 2008-12-05 | 2011-08-26 | Philippe Perovitch | Dispositif de conditionnement et d'administration de principes actifs en solution hydro-alcoolique. |
FR2940116B1 (fr) * | 2008-12-22 | 2012-07-06 | Philippe Perovitch | Formulation pour l'administration d'hypolipemiant par voie trans-muqueuse buccale |
FR2940911B1 (fr) * | 2009-01-13 | 2012-09-21 | Philippe Perovitch | Formulation pour l'administration par voie trans-muqueuse buccale de molecules antalgiques et/ou anti-spasmodiques |
FR2947729B1 (fr) * | 2009-07-10 | 2012-01-20 | Philippe Perovitch | Composition pharmaceutique pour le traitement du diabete de type ii par voie trans-muqueuse buccale |
-
2013
- 2013-01-14 FR FR1350308A patent/FR3000896B1/fr not_active Expired - Fee Related
-
2014
- 2014-01-14 CN CN201480011684.3A patent/CN105025880A/zh active Pending
- 2014-01-14 EP EP14703148.8A patent/EP2943182A1/fr active Pending
- 2014-01-14 MX MX2015009027A patent/MX2015009027A/es unknown
- 2014-01-14 RU RU2015134148A patent/RU2015134148A/ru not_active Application Discontinuation
- 2014-01-14 JP JP2015552133A patent/JP2016504405A/ja active Pending
- 2014-01-14 CA CA2897685A patent/CA2897685A1/fr not_active Abandoned
- 2014-01-14 US US14/759,822 patent/US20150352038A1/en not_active Abandoned
- 2014-01-14 WO PCT/FR2014/050070 patent/WO2014108657A1/fr active Application Filing
- 2014-01-14 BR BR112015016869A patent/BR112015016869A2/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2015134148A (ru) | 2017-02-16 |
JP2016504405A (ja) | 2016-02-12 |
WO2014108657A1 (fr) | 2014-07-17 |
BR112015016869A2 (pt) | 2017-07-11 |
EP2943182A1 (fr) | 2015-11-18 |
MX2015009027A (es) | 2016-01-20 |
US20150352038A1 (en) | 2015-12-10 |
FR3000896A1 (fr) | 2014-07-18 |
CA2897685A1 (fr) | 2014-07-17 |
CN105025880A (zh) | 2015-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR3000896B1 (fr) | Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil | |
BR112013029246A2 (pt) | 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico | |
BR112017003546A2 (pt) | amidas heterocíclicas como inibidores de rip1 quinase como medicamentos | |
CO7141411A2 (es) | Formulaciones y métodos para la administración vaginal de antiprogestinas | |
MA47069A (fr) | Formes pharmaceutiques contenant des inhibiteurs des canaux task-1 et task-3 et leur utilisation pour le traitement de troubles respiratoires | |
MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
MA47074A (fr) | Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires | |
FR3032353B1 (fr) | Composition pharmaceutique et dispositif pour le traitement de la douleur | |
MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
FR20C1026I1 (fr) | Ciclesonide pour le traitement de maladies des voies respiratoires chez les chevaux | |
EA201500112A1 (ru) | 3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств | |
MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
MY183526A (en) | Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof | |
MA38253B1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
FR2986156B1 (fr) | Dispositif transdermique pour l'administration controlee a un patient d'au moins un principe actif | |
LU91982B1 (fr) | Combinaison et utilisation des plantes issues de la médecine traditionnelle chinoise pour la prévention et le traitement des néphropathies | |
MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
EA201390398A1 (ru) | Арилсульфонамиды для лечения заболеваний цнс | |
FR2997837B1 (fr) | Dispositif d'osteosynthese pour le traitement des fractures du col de femur. | |
MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
FR3012329B1 (fr) | Association vitamine c et acide hyaluronique pour le traitement des effets du vieillissement cutane. | |
EA201501173A1 (ru) | Применение адсорбированного гомогената трутневого расплода и витаминов группы d и/или их активных метаболитов для профилактики и лечения острых респираторных заболеваний и гриппа | |
FR3005411B1 (fr) | Association d'actifs pour une administration par voie orale pour ameliorer la qualite des ongles. | |
MA47467A (fr) | Compositions phytothérapeutiques d'eschscholzia california et méthode pour le traitement de troubles du sommeil et oniriques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 3 |
|
PLFP | Fee payment |
Year of fee payment: 4 |
|
PLFP | Fee payment |
Year of fee payment: 5 |
|
PLFP | Fee payment |
Year of fee payment: 6 |
|
ST | Notification of lapse |
Effective date: 20190906 |